- Cancer Types
Information about risk, prevention, screening, symptoms, diagnosis, treatment, and support for all cancers Cancer A to Z - Cancer Treatment
Cancer Treatment
Information about cancer treatment, including surgery, chemotherapy, radiation therapy, clinical trials, proton therapy, complementary medicine, and cutting edge technologies.
- Risk and Prevention
- Cancer Drugs
- Support
Support
Ways for cancer patients and caregivers to cope with cancer, side effects, nutrition, general cancer support issues, grief/end of life issues, and shared survivor's experiences.
- Healthcare Professionals
- Clinical Trials
My Patient Treatment Binder
OncoLink Blogs
What's My Cancer Risk?
OncoPilot: Navigating Your Cancer Journey
Community Events Calendar
OncoLink eNews
Abramson Cancer CenterNews
News stories related to carcinoid and neuroendocrine tumors.
 Social Network, Early Breast Cancer Prognosis Link ExploredNov 14, 2012 For women with early-stage breast cancer, large social networks predict better prognosis, and this association varies based on social support and burden, according to a study published online Nov. 9 in Breast Cancer Research and Treatment. |
 Negative Pigment Network Able to Distinguish MelanomaOct 26, 2012 Negative pigment network can be used to distinguish melanoma from Spitz nevus and other benign lesions, according to a study published online Oct. 11 in the Journal of the American Academy of Dermatology. |
 Chemo Combo Promising for Pancreatic Neuroendocrine TumorsJul 17, 2012 The combination of temozolomide and bevacizumab seems to benefit patients with advanced pancreatic neuroendocrine tumors, according to a study published online July 9 in the Journal of Clinical Oncology. |
 Cervical Cancer Mortality Similar in U.S. and NetherlandsMar 27, 2012 The cervical cancer screening program used by the Netherlands is as effective as the screening protocol used in the United States, producing similar cervical cancer mortality rates in spite of less screening, according to research published in the March issue of the Milbank Quarterly. |
 Everolimus Ups Survival in Carcinoid SyndromeNov 29, 2011 For patients with low- or intermediate-grade advanced neuroendocrine tumors (carcinoids), everolimus plus octreotide long-acting repeatable (LAR) improves progression-free survival versus placebo plus octreotide LAR, according to a study published online Nov. 25 in The Lancet. |
Cancer Types
Bone Cancer
Brain Tumors
Breast Cancer
Carcinoid Tumors
Endocrine System Cancers
Gastrointestinal Cancers
Gynecologic Cancers
Head and Neck Cancers
Leukemia
Lung Cancers
Lymphomas
Myelomas
Pediatric Cancers
Penile Cancer
Prostate Cancer
Sarcomas
Skin Cancers
Testicular Cancer
Thyroid Cancer
Urinary Tract Cancers
OncoLink Vet
Cancer Treatment
Biologic Therapy
Bone Marrow Transplants
Chemotherapy
Clinical Trials
Complementary Medicine
Gene Therapy
General Treatment Concerns
Hormone Therapy
PDT Center
Proton Therapy
Radiation Oncology
Surgical Oncology
Targeted Therapies
Vaccine Therapies
Cancer Support
Caregivers
Hospice Care and Bereavement
Nutrition and Cancer
Sexuality & Fertility
Side Effects
Support
Survivorship
Exercise and Cancer
Cancer Resources
Cancer News
OncoLink University
Nurses' Notes
Conferences
Newly Diagnosed Patients
Causes and Prevention
Legal and Financial Information for Patients
LGBT Resources
NCI Resources
Global Resources
Cancer Resource List
Resources for Young Adults
OncoLink Media Library
OncoLink TV
Book, Music and Video Reviews
Ask the Experts
Brown Bag Chat
Tracy's Corner
About OncoLink
About OncoLink
Giving to OncoLink
Contact Information
Usage Policy
Editorial Board
How to Partner with OncoLink
Link to OncoLink
Mission Statement
